REPLIGEN CORP (RGEN) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 56.97M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 33.29M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 64.61M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $56.97M | (m) | $33.29M | $64.61M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $56.52M | (m) | $33.65M | $64.53M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $54.18M | (m) | $32.60M | $55.17M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $52.73M | (m) | $30.98M | $798.00K | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $48.27M | (m) | $45.06M | $-23.86M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $44.89M | (m) | $46.57M | $-32.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $43.20M | (m) | $48.07M | $-35.11M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $41.81M | (m) | $48.18M | $11.26M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $42.67M | (m) | $30.83M | $7.44M | $11.28M | (m) | (m) | 0.66× | Reported |
| 2024-03-31 | $41.81M | (m) | $27.10M | $25.35M | $6.57M | (m) | (m) | 3.86× | Reported |
| 2023-12-31 | $42.72M | (m) | $25.57M | $54.58M | $1.95M | (m) | (m) | 27.97× | Reported |
| 2023-09-30 | $43.55M | (m) | $25.37M | $104.30M | $1.08M | (m) | (m) | 96.31× | Reported |
| 2023-06-30 | $43.20M | (m) | $25.15M | $152.16M | $1.14M | (m) | (m) | 133.12× | Reported |
| 2023-03-31 | $43.94M | (m) | $26.66M | $195.93M | $1.14M | (m) | (m) | 171.86× | Reported |
| 2022-12-31 | $43.94M | (m) | $27.32M | $224.67M | $1.16M | (m) | (m) | 193.35× | Reported |
| 2022-09-30 | $41.94M | (m) | $28.08M | $213.26M | $5.21M | (m) | (m) | 40.97× | Reported |
| 2022-06-30 | $40.87M | (m) | $28.72M | $205.79M | $7.74M | (m) | (m) | 26.60× | Reported |
| 2022-03-31 | $38.82M | (m) | $28.87M | $190.87M | $10.25M | (m) | (m) | 18.62× | Reported |
| 2021-12-31 | $34.27M | (m) | $27.50M | $167.25M | $12.71M | (m) | (m) | 13.15× | Reported |
| 2021-09-30 | $31.88M | (m) | $24.99M | $147.24M | $12.57M | (m) | (m) | 11.71× | Reported |
| 2021-06-30 | $27.14M | (m) | $22.42M | $123.00M | $12.40M | (m) | (m) | 9.92× | Reported |
| 2021-03-31 | $23.09M | (m) | $19.38M | $94.30M | $12.26M | (m) | (m) | 7.69× | Reported |
| 2020-12-31 | $20.18M | (m) | $17.01M | $69.82M | $12.13M | (m) | (m) | 5.75× | Reported |
| 2020-09-30 | $18.63M | (m) | $15.88M | $58.30M | $12.00M | (m) | (m) | 4.86× | Reported |
| 2020-06-30 | $19.64M | (m) | $14.83M | $45.30M | $11.80M | (m) | (m) | 3.84× | Reported |
| 2020-03-31 | $20.53M | (m) | $13.76M | $36.82M | $10.54M | (m) | (m) | 3.49× | Reported |
| 2019-12-31 | $19.45M | (m) | $12.85M | $36.08M | $9.29M | (m) | (m) | 3.88× | Reported |
| 2019-09-30 | $17.43M | (m) | $11.98M | $38.04M | $8.03M | (m) | (m) | 4.74× | Reported |
| 2019-06-30 | $15.60M | (m) | $11.58M | $37.96M | $6.86M | (m) | (m) | 5.54× | Reported |
| 2019-03-31 | $16.15M | (m) | $11.18M | $31.18M | $6.78M | (m) | (m) | 4.60× | Reported |
| 2018-12-31 | $15.82M | (m) | $10.19M | $25.99M | $6.71M | (m) | (m) | 3.87× | Reported |
| 2018-09-30 | $15.74M | (m) | $9.57M | $21.40M | $6.64M | (m) | (m) | 3.22× | Reported |
| 2018-06-30 | $14.14M | (m) | $8.61M | $13.10M | $6.58M | (m) | (m) | 1.99× | Reported |
| 2018-03-31 | $10.22M | $155.48M | $7.48M | $14.30M | $6.51M | 6.57% | 4.81% | 2.20× | Reported |
| 2017-12-31 | $8.67M | $141.24M | $6.75M | $14.01M | $6.44M | 6.14% | 4.78% | 2.17× | Reported |
| 2017-09-30 | $7.64M | $125.22M | $6.10M | $13.65M | $6.37M | 6.10% | 4.87% | 2.14× | Reported |
| 2017-06-30 | $7.53M | $113.32M | $5.56M | $17.80M | $6.31M | 6.64% | 4.91% | 2.82× | Reported |
| 2017-03-31 | $7.56M | $110.04M | $5.20M | $18.19M | $5.35M | 6.87% | 4.73% | 3.40× | Reported |
| 2016-12-31 | $7.36M | $104.54M | $4.59M | $15.97M | $3.77M | 7.04% | 4.40% | 4.24× | Reported |
| 2016-09-30 | $6.75M | (m) | $4.27M | $14.50M | $2.21M | (m) | (m) | 6.57× | Reported |
| 2016-06-30 | $6.35M | (m) | $3.97M | $14.44M | $658.00K | (m) | (m) | 21.94× | Reported |
| 2016-03-31 | $5.71M | (m) | $3.82M | $13.19M | $28.00K | (m) | (m) | 471.04× | Reported |
| 2015-12-31 | $5.74M | $83.54M | $3.60M | $13.76M | $32.00K | 6.87% | 4.31% | 430.13× | Reported |
| 2015-09-30 | $5.64M | $78.48M | $3.05M | $12.40M | $35.96K | 7.18% | 3.88% | 344.77× | Reported |
| 2015-06-30 | $5.80M | $73.94M | $2.60M | $10.92M | $39.92K | 7.84% | 3.52% | 273.67× | Reported |
| 2015-03-31 | $5.98M | $68.04M | $2.16M | $9.42M | $44.91K | 8.78% | 3.18% | 209.79× | Reported |
| 2014-12-31 | $5.61M | $63.55M | $1.77M | $10.69M | $49.96K | 8.83% | 2.78% | 214.01× | Reported |
| 2014-09-30 | $5.70M | $62.54M | $1.68M | $15.81M | $50.57K | 9.12% | 2.68% | 312.73× | Reported |
| 2014-06-30 | $5.48M | $66.08M | $1.35M | $21.64M | $50.78K | 8.30% | 2.04% | 426.13× | Reported |
| 2014-03-31 | $6.36M | $68.04M | $1.12M | $24.64M | $50.40K | 9.34% | 1.64% | 488.78× | Reported |
| 2013-12-31 | $7.34M | $68.17M | $1.06M | $22.87M | $49.85K | 10.77% | 1.55% | 458.85× | Reported |
| 2013-09-30 | $8.26M | $71.60M | $1.05M | $24.10M | (m) | 11.54% | 1.46% | (m) | (m) |
| 2013-06-30 | $9.27M | $67.88M | $1.13M | $18.25M | $32.91K | 13.65% | 1.67% | 554.49× | Reported |
| 2013-03-31 | $9.86M | $65.90M | $1.03M | $13.46M | $47.86K | 14.97% | 1.57% | 281.24× | Reported |
| 2012-12-31 | $10.49M | $62.27M | $1.02M | $11.08M | $56.71K | 16.85% | 1.64% | 195.42× | Reported |
| 2012-09-30 | $11.02M | $50.62M | $947.39K | $3.13M | (m) | 21.77% | 1.87% | (m) | (m) |
| 2012-06-30 | $11.66M | $44.14M | $904.01K | $1.50M | (m) | 26.41% | 2.05% | (m) | (m) |
| 2012-03-31 | $12.27M | $36.27M | $971.01K | $60.01K | (m) | 33.83% | 2.68% | (m) | (m) |
| 2011-12-31 | $13.25M | $29.36M | $985.17K | $-3.19M | $41.26K | 45.12% | 3.36% | -77.41× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $12.53M | $27.29M | $1.00M | $-374.07K | $26.17K | 45.91% | 3.68% | -14.30× | Reported |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $14.16M | $20.97M | $1.01M | $-5.77M | $1.97K | 67.52% | 4.80% | -2924.28× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |